首页> 外文学位 >I. The development of estrogen receptor coactivator binding inhibitors. II. Investigations into the binding modes of ligands selective for estrogen receptor alpha.
【24h】

I. The development of estrogen receptor coactivator binding inhibitors. II. Investigations into the binding modes of ligands selective for estrogen receptor alpha.

机译:I.雌激素受体共激活剂结合抑制剂的发展。二。研究对雌激素受体α具有选择性的配体的结合模式。

获取原文
获取原文并翻译 | 示例

摘要

Based on our analysis of a recent X-ray crystal structure of the ERα ligand binding domain complexed to a helical peptide containing a single nuclear receptor box motif, we have designed a series of small molecules to inhibit the binding of p160 coactivator proteins to the ER. This is a novel approach to blocking ER action because we are attempting to interrupt the pathway at a point subsequent to hormone binding.; A variety of compounds based on aromatic cores including triazene, pyrimidine, and naphthalene have been synthesized. Two in vitro assays utilizing fluorescence polarization and fluorescence resonance energy transfer have been developed to test the compounds for ER binding and inhibition of coactivator recruitment. The most promising class of CBIs proved to be compounds with a pyrimidine core, which displaced a coactivator peptide from the ER with Ki's equal to approximately 30 μM. This work provides the first examples of non-peptide coactivator binding inhibitors that we are aware of.; There are two genes for the estrogen receptor, the classical ERα and the more recently discovered ERβ. Though the receptors share significant sequence identity, they have a different tissue distribution, ligand specificity, and possibly biological roles. The development of modulators selective for one subtype over the other could help in understanding the physiological significance of the two receptors.; Our laboratory has previously discovered that certain heterocycles show high binding affinity and selectivity for ERα. In order to design more potent and selective derivatives, a better understanding of how they bind to the receptor is needed. Using a comparative binding analysis method and molecular modeling, we were able to assess the binding mode of a furan agonist and antagonist. As an agonist, the furan binds to the receptor with the C(2) phenol acting as the A-ring in most cases. As an antagonist, the furan binds with the C(5) phenol acting as the A-ring mimic and the basic side chain extending back into the pocket in a similar fashion to known antagonists. The preparation of various mono and bisphenolic furan analogs in conjunction with molecular modeling assisted in confirming these assertions.
机译:基于我们对与包含单个核受体盒基序的螺旋肽复合的ERα配体结合域的最新X射线晶体结构的分析,我们设计了一系列小分子来抑制p160共激活蛋白与ER的结合。这是一种新型的阻断ER作用的方法,因为我们正试图在激素结合后的某个时间点中断该途径。已经合成了多种基于芳族核的化合物,包括三嗪,嘧啶和萘。已经开发了两种利用荧光偏振和荧光共振能量转移的“体外”试验来测试化合物的ER结合和抑制共激活剂募集。事实证明,最有前途的一类CBI是具有嘧啶核的化合物,该化合物将ER上的共激活肽从K i 置换为大约30μM。这项工作提供了我们知道的非肽共激活因子结合抑制剂的第一个例子。雌激素受体有两个基因,经典的ERα和最近发现的ERβ。尽管受体具有显着的序列同一性,但它们具有不同的组织分布,配体特异性以及可能的生物学作用。对一种亚型比另一种亚型具有选择性的调节剂的开发可以帮助理解这两种受体的生理学意义。我们的实验室先前发现某些杂环对ERα具有高结合亲和力和选择性。为了设计更有效和选择性的衍生物,需要更好地了解它们如何与受体结合。使用比较结合分析方法和分子建模,我们能够评估呋喃激动剂和拮抗剂的结合模式。作为激动剂,呋喃在大多数情况下以C(2)酚作为A环与受体结合。作为拮抗剂,呋喃与充当A环模拟物的C(5)酚结合,并且基本侧链以与已知拮抗剂类似的方式延伸回到口袋中。各种单酚和双酚呋喃类似物的制备以及分子模型的结合有助于确认这些主张。

著录项

  • 作者

    Rodriguez, Alice Lambert.;

  • 作者单位

    University of Illinois at Urbana-Champaign.;

  • 授予单位 University of Illinois at Urbana-Champaign.;
  • 学科 Chemistry Organic.; Biology Molecular.
  • 学位 Ph.D.
  • 年度 2003
  • 页码 153 p.
  • 总页数 153
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 有机化学;分子遗传学;
  • 关键词

  • 入库时间 2022-08-17 11:45:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号